Bio-rad Laboratories, INC

Bio-Rad Laboratories stockholders approved the amended 2017 Incentive Award Plan and re-elected all director nominees at the 2026 Annual Meeting.

Bio-Rad Laboratories, Inc. disclosed key financial results for its investment in Sartorius AG for the year ended December 31, 2025.

Bio-Rad Laboratories announced modest revenue growth and strong free cash flow for 2025, but gross and operating margins fell below expectations amid challenging market conditions.

Bio-Rad Laboratories announced third-quarter 2025 financial results, reporting modest revenue growth and a better-than-expected operating margin despite market challenges.

Bio-Rad Laboratories, Inc. announced the passing of its co-founder and Director Emeritus, Alice N. Schwartz, at the age of 99.

Bio-Rad Laboratories details its Droplet Digital PCR portfolio, emphasizing its market leadership and future growth opportunities in a recent informational webinar.

Bio-Rad Laboratories' Q2 2026 report shows flat net sales, with a decline in Life Science offset by modest growth in Clinical Diagnostics, while managing significant market uncertainties and a substantial investment portfolio.

Bio-Rad Laboratories reported a net loss of $527.1 million for Q1 2026, primarily driven by a significant decline in the fair market value of its investment in Sartorius AG.

Bio-Rad Laboratories reported a net loss for the third quarter of 2025, primarily driven by a significant decline in the fair value of its investment in Sartorius AG, despite a slight increase in net sales.

Bio-Rad Laboratories reported a significant net income of $317.8 million for the second quarter of 2025, primarily due to a $334.4 million gain from its Sartorius AG equity investment, despite a slight 2.1% increase in net sales and ongoing operational cost pressures.

Bio-Rad Laboratories' Q1 2025 sales decreased by 4.2% year-over-year, impacted by challenges in the life science segment and restructuring activities.

Bio-Rad Laboratories' Q3 2024 results show a net income of $653.2 million, heavily influenced by gains in fair market value of equity securities, while facing challenges in the Life Science segment.

Bio-Rad Laboratories' 2024 results were significantly impacted by losses from changes in the fair market value of its investment in Sartorius AG, leading to a substantial net loss, while the company also announced a restructuring plan to improve operating performance.

Bio-Rad Laboratories experienced a decrease in net sales for 2023, impacted by global economic conditions and biopharma market constraints, while also navigating strategic restructuring efforts.

Eva Anette Engelhardt, EVP, President, CDG of Bio-Rad Laboratories, Inc., reported multiple transactions in common stock on July 25, 2026.

Bio-Rad Laboratories' EVP and CFO, Roop Kalyan Lakkaraju, acquired 1,078 shares of Class A common stock upon the vesting of restricted stock units.

Courtney C. Enloe, EVP, General Counsel & Secretary of Bio-Rad Laboratories, Inc., acquired shares through the vesting of restricted stock units and participation in the Employee Stock Purchase Plan.

Bio-Rad Laboratories Director Greg K. Hinckley acquired shares of Class A common stock upon the vesting of restricted stock units.

Bio-Rad Laboratories Director Melinda Litherland reported transactions involving the acquisition of Class A common stock upon the vesting of restricted stock units.

Bio-Rad Laboratories Director Jeffrey L. Edwards acquired shares of Class A common stock upon the vesting of restricted stock units.

Bio-Rad Laboratories, Inc. issues its 2026 proxy statement, seeking approval for director elections, auditor ratification, executive compensation, and an expanded equity incentive plan, while facing a shareholder proposal to eliminate its dual-class stock structure.

Bio-Rad Laboratories will hold its annual stockholders meeting on April 22, 2025, to vote on director elections, auditor ratification, and an executive severance proposal.

Bio-Rad Laboratories is set to hold its annual stockholder meeting on April 23, 2024, to vote on director elections, auditor ratification, and approval of an amended incentive award plan.

Norman D. Schwartz consolidates significant beneficial ownership of Bio-Rad Laboratories Class B Common Stock following the passing of Alice N. Schwartz, maintaining family control.

Norman D. Schwartz has consolidated beneficial ownership and control over Bio-Rad Laboratories' Class A and Class B Common Stock following the passing of Alice N. Schwartz.

Norman D. Schwartz consolidates control of Bio-Rad Laboratories' Class B Common Stock following the death of Alice N. Schwartz, becoming the sole trustee of key family trusts.

Norman D. Schwartz assumes sole trustee roles for significant Bio-Rad Laboratories, Inc. Class A Common Stock trusts following the passing of Alice N. Schwartz, consolidating family control.

An amended Schedule 13D filing reveals Alice N. Schwartz and her revocable trust continue to hold substantial Class A and Class B common stock, solidifying family control over Bio-Rad Laboratories, primarily for estate planning purposes.

BlackRock, Inc. has reported an aggregate beneficial ownership of 7.4% of Bio-Rad Laboratories, Inc.'s Class A Stock, totaling 1,618,123 shares.

First Eagle Investment Management and its Global Fund have reported an 11.4% beneficial ownership stake in Bio-Rad Laboratories Inc.

First Eagle Investment Management, LLC and its affiliate, First Eagle Global Fund, have disclosed a significant beneficial ownership stake of 10.0% in Bio-Rad Laboratories Inc.'s common stock.

First Eagle Investment Management, LLC has reported a significant beneficial ownership stake of 6.8% in Bio-Rad Laboratories Inc., as detailed in a recent Schedule 13G filing with the SEC.

Bio-Rad Laboratories, Inc. has filed an amended Schedule 13G, confirming its beneficial ownership of 9.66% of Oncocyte Corporation's common shares as of February 10, 2025.